Results 21 to 30 of about 11,328,563 (174)

Post-marketing safety signals and report-level ARIA-E stratification for lecanemab and donanemab: an integrated FAERS and WHO-VigiAccess pharmacovigilance study. [PDF]

Ther Adv Drug Saf
Background: Anti-β-amyloid monoclonal antibodies provide a disease-modifying treatment approach for Alzheimer’s disease, but post-marketing safety concerns remain, particularly amyloid-related imaging abnormalities (ARIA).
Xue WY, Li X, Li WT, Qin BZ, Wang CZ, Liu T, Wang M.   +6 more
europepmc   +2 more sources

Fluid and Imaging Biomarkers in Lecanemab Therapy for Early Alzheimer’s Disease: Current Evidence, ARIA Risk Prediction, and Treatment Monitoring

Journal of Dementia and Alzheimer's Disease
Background/Objectives: Lecanemab, a humanized anti-amyloid-β protofibril antibody, achieves substantial amyloid clearance and modest slowing of clinical decline in early Alzheimer’s disease (AD). Amyloid-related imaging abnormalities (ARIA) represent the
Pan-Woo Ko
doaj   +2 more sources

Amyloid-related imaging abnormalities (ARIA) in Alzheimer's immunotherapy: a framework and challenges for global surveillance strategies. [PDF]

J Neurol Neurosurg Psychiatry
Hu N, Yang X, Feng F, Zhang B, Liu Y, Gao H, Chen Q, Zhang CJ, Chen X, Yan F, Haller S, Lui S.   +11 more
europepmc   +3 more sources

Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy-Related Inflammation: A Multicenter Prospective Longitudinal Cohort Study [PDF]

, 2021
To investigate the natural history and outcomes following treatment for spontaneous amyloid-related imaging abnormalities (ARIA)-like in cerebral amyloid angiopathy-related inflammation (CAA-ri)
Pascarella, Rosario, Masafumi Ihara, Perini, Giulia, Shima, Atsushi, Ricardo Nitrini, Roberto Marconi, Maria Sessa, Laura Antolini, Domenico Inzitari, Rosario Pascarella, Valenti, Raffaella, Gianpaolo Basso, Di Lazzaro, Vincenzo, Alessia Giossi, Charidimou, Andreas, Andreas Charidimou, Marcon, Michela, Roxana O. Carare, Andrea Arighi, Carare, Roxana, Tagliavini, Fabrizio, Elio Scarpini, and Fabrizio Piazza, Jacopo C. DiFrancesco, Mario Cirillo, Hagiwara, Yuta, Zedde, Marialuisa, Raffaella Valenti, Fabrizio Tagliavini, Berardino Orlandi, Villarejo-Galende, Alberto, Carare, Roxana O, Carlo Ferrarese, Vincenzo Di Lazzaro, Marialuisa Zedde, Sessa, Maria, Inzitari, Domenico, Arighi, Andrea, Basso, Gianpaolo, Marconi, Roberto, Nitrini, Ricardo, Cirillo, Mario, Michela Marcon, Ziliotto, Nicole, Alessandro Padovani, Alberto Villarejo-Galende, Yuta Hagiwara, Scarpini, Elio, Massimo Caulo, Francesco Perini, Piazza, Fabrizio, Cagnin, Annachiara, Caulo, Massimo, Juan Francisco Vazquez-Costa, Nicole Ziliotto, Antolini, Laura, Vázquez-Costa, Juan Francisco, Ferrarese, Carlo, Padovani, Alessandro, Ihara, Masafumi, Perini, Francesco, Atsushi Shima, DiFrancesco, Jacopo C, Annachiara Cagnin, Giossi, Alessia, Giulia Perini, Orlandi, Berardino, Ziliotto N., Caulo M., Scarpini E., Charidimou A., Marcon M., Marconi R., Carare R. O., Piazza F., Padovani A., Sessa M., Tagliavini F., Orlandi B., Arighi A., Perini F., Basso G., Giossi A., Cirillo M., Villarejo-Galende A., Cagnin A., Di Lazzaro V., Valenti R., Antolini L., Ferrarese C., Pascarella R., Nitrini R., DiFrancesco J. C., Shima A., Ihara M., Hagiwara Y., Perini G., Zedde M., Vazquez-Costa J. F., Inzitari D., Fabrizio Piazza   +100 more
core   +1 more source

Spectrum of amyloid-related imaging abnormalities associated with aducanumab treatment: a case series report. [PDF]

BMC Neurol
Background Amyloid-related imaging abnormalities (ARIA) observed on magnetic resonance imaging (MRI) are known adverse events associated with beta-amyloid plaque-lowering monoclonal antibodies.
Atri A, Curiale GG, Aisen P, Barakos J, Purcell D, Bracoud L, Haeberlein SB, Grassi C, Hughes R, Smirnakis K.   +9 more
europepmc   +2 more sources

SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA). [PDF]

Alzheimers Res Ther, 2018
Anti-amyloid β (Aβ) immunotherapy represents a major area of drug development for Alzheimer's disease (AD). However, Aβ peptide adopts multiple conformations and the pathological forms to be specifically targeted have not been identified. Aβ immunotherapy-related vasogenic edema has also been severely dose limiting for antibodies with effector ...
Pradier L, Blanchard-Brégeon V, Bohme A, Debeir T, Menager J, Benoit P, Barneoud P, Taupin V, Bertrand P, Dugay P, Cameron B, Shi Y, Naimi S, Duchesne M, Gagnaire M, Weeden T, Travaline T, Reczek D, Khiroug L, Slaoui M, Brunel P, Fukuyama H, Ravetch J, Canton T, Cohen C.   +24 more
europepmc   +5 more sources

Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup. [PDF]

Alzheimers Dement
Abstract In 2011, a workgroup of the Alzheimer's Association Research Roundtable introduced recommendations for detecting and monitoring amyloid‐related imaging abnormalities (ARIA) in Alzheimer's disease (AD) clinical trials. Since then, anti‐amyloid immunotherapies have received regulatory approval for AD treatment and are beginning
van Etten ES, Mahinrad S, Grill JD, Salloway S, Atri A, Cogswell PM, Benzinger TLS, Iwatsubo T, Iadecola C, Lemere CA, Nicoll JAR, Greenberg SM, Carrillo MC, Jack CR, Sperling RA.   +14 more
europepmc   +2 more sources

Amyloid-related imaging abnormalities (ARIA) and their radiological, biological and clinical characteristics: a plain language summary. [PDF]

Neurodegener Dis Manag
WHAT IS THIS SUMMARY ABOUT? This is a plain language summary of an article published in the journal Brain. People with Alzheimer's disease may receive treatments that target amyloid-β – a protein in the brain that is one of the key characteristics of Alzheimer's disease when it is present in higher levels than normal.
Hampel H, Elhage A, Cho M, Nicoll JA, Atri A.   +4 more
europepmc   +3 more sources

Amyloid-related Imaging Abnormalities (ARIA) in the Context of Alzheimer's Disease and Amyloid-targeting Therapies: An Introduction for Advanced Practice Providers. [PDF]

Drugs Aging
Alzheimer's disease (AD) is a progressive neurodegenerative disorder pathologically characterized by the accumulation of amyloid-beta (Aβ) and neurofibrillary tangles of hyperphosphorylated tau in the brain. Amyloid-targeting therapies (ATTs) are the first available disease-modifying treatments shown to slow cognitive and functional decline for ...
Schreiber CP, Kovacik A, Bishop J, Helman J.   +3 more
europepmc   +4 more sources

MRI‐histopathology correlations of amyloid‐related imaging abnormalities (ARIA) in postmortem human brain samples [PDF]

Alzheimer's & Dementia, 2020
AbstractBackgroundAmyloid‐related imaging abnormalities (ARIA) on MRI are frequently observed adverse advents in the context of anti‐Aβ immunotherapy trials in patients with Alzheimer’s disease (AD). The underlying histopathology and mechanisms of ARIA remain unknown, although coexisting Cerebral Amyloid Angiopathy (CAA) appears to be a risk factor ...
Ashley Scherlek, Mariel Kozberg, James A.R. Nicoll, Brian Bacskai, Steven M. Greenberg, Matthew P. Frosch, Delphine Boche, Susanne J. Veluw   +7 more
openaire   +1 more source